开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=2190033, encodeId=46772190033b4, content=投稿3个月，状态从In Peer Review 改为Under Consideration，请问这是什么意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Thu Feb 29 09:33:12 CST 2024, time=2024-02-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2213045, encodeId=670d221304518, content=2.20投稿 5.13大修 6.7小修 7.2接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Wed Jul 03 17:39:19 CST 2024, time=2024-07-03, status=1, ipAttribution=塔斯马尼亚), GetPortalCommentsPageByObjectIdResponse(id=2206958, encodeId=90652206958b2, content=急求大神future oncology引文格式怎么弄啊，用endnote哪个格式和这个杂志一样啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8db8225594, createdName=ms7000000025099510, createdTime=Tue May 28 00:50:15 CST 2024, time=2024-05-28, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2206954, encodeId=6949220695495, content=求各位大神该杂志引文格式endnote里没有，选哪个比较接近？急急急，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8db8225594, createdName=ms7000000025099510, createdTime=Tue May 28 00:06:43 CST 2024, time=2024-05-28, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2126415, encodeId=ba74212641530, content=请问大家外审一般要多久啊，我1-26提交的仍然是in peer review，快三个月了都。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:12:09 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2112771, encodeId=77502112e71ff, content=这个杂志接受综述吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35248523751, createdName=ms6000000603665223, createdTime=Thu Feb 02 17:46:47 CST 2023, time=2023-02-02, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2108166, encodeId=339d2108166e5, content=兄弟们，这个期刊要不要综述啊，不是约稿的那种, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a298489693, createdName=ms2000000288456127, createdTime=Fri Dec 30 18:04:27 CST 2022, time=2022-12-30, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2108547, encodeId=6e9e210854e2c, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;放疗;基础研究 经验分享：期刊非常非常慢，去年10月投稿，今年12月接收，期间一直在under review，审稿人和编辑一起提了30多个问题，response letter字数比原文还长。。。。谨慎投兄弟们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18652547957, createdName=125366dam34暂无昵称, createdTime=Mon Jan 02 20:26:32 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126414, encodeId=a03a212641436, content=请问外审一般要多久呀？我是1-26提交的，目前仍然是in peer review。。。快三个月了5555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:09:36 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2128668, encodeId=b2e92128668cb, content=有朋友知道怎么获得future oncology 2022的全部关于肝癌的论文吗？有资源的帮帮我？电话18670664356, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af418118021, createdName=ms6000000107141238, createdTime=Thu Apr 27 14:51:33 CST 2023, time=2023-04-27, status=1, ipAttribution=上海)]

2024-02-29 重复的用户名来自浙江省

投稿3个月，状态从In Peer Review 改为Under Consideration，请问这是什么意思？

80 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2190033, encodeId=46772190033b4, content=投稿3个月，状态从In Peer Review 改为Under Consideration，请问这是什么意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Thu Feb 29 09:33:12 CST 2024, time=2024-02-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2213045, encodeId=670d221304518, content=2.20投稿 5.13大修 6.7小修 7.2接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Wed Jul 03 17:39:19 CST 2024, time=2024-07-03, status=1, ipAttribution=塔斯马尼亚), GetPortalCommentsPageByObjectIdResponse(id=2206958, encodeId=90652206958b2, content=急求大神future oncology引文格式怎么弄啊，用endnote哪个格式和这个杂志一样啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8db8225594, createdName=ms7000000025099510, createdTime=Tue May 28 00:50:15 CST 2024, time=2024-05-28, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2206954, encodeId=6949220695495, content=求各位大神该杂志引文格式endnote里没有，选哪个比较接近？急急急，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8db8225594, createdName=ms7000000025099510, createdTime=Tue May 28 00:06:43 CST 2024, time=2024-05-28, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2126415, encodeId=ba74212641530, content=请问大家外审一般要多久啊，我1-26提交的仍然是in peer review，快三个月了都。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:12:09 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2112771, encodeId=77502112e71ff, content=这个杂志接受综述吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35248523751, createdName=ms6000000603665223, createdTime=Thu Feb 02 17:46:47 CST 2023, time=2023-02-02, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2108166, encodeId=339d2108166e5, content=兄弟们，这个期刊要不要综述啊，不是约稿的那种, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a298489693, createdName=ms2000000288456127, createdTime=Fri Dec 30 18:04:27 CST 2022, time=2022-12-30, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2108547, encodeId=6e9e210854e2c, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;放疗;基础研究 经验分享：期刊非常非常慢，去年10月投稿，今年12月接收，期间一直在under review，审稿人和编辑一起提了30多个问题，response letter字数比原文还长。。。。谨慎投兄弟们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18652547957, createdName=125366dam34暂无昵称, createdTime=Mon Jan 02 20:26:32 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126414, encodeId=a03a212641436, content=请问外审一般要多久呀？我是1-26提交的，目前仍然是in peer review。。。快三个月了5555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:09:36 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2128668, encodeId=b2e92128668cb, content=有朋友知道怎么获得future oncology 2022的全部关于肝癌的论文吗？有资源的帮帮我？电话18670664356, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af418118021, createdName=ms6000000107141238, createdTime=Thu Apr 27 14:51:33 CST 2023, time=2023-04-27, status=1, ipAttribution=上海)]

2024-07-03 凶巴巴恰北北怪兽来自塔斯马尼亚

2.20投稿 5.13大修 6.7小修 7.2接收

59 0

[GetPortalCommentsPageByObjectIdResponse(id=2190033, encodeId=46772190033b4, content=投稿3个月，状态从In Peer Review 改为Under Consideration，请问这是什么意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Thu Feb 29 09:33:12 CST 2024, time=2024-02-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2213045, encodeId=670d221304518, content=2.20投稿 5.13大修 6.7小修 7.2接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Wed Jul 03 17:39:19 CST 2024, time=2024-07-03, status=1, ipAttribution=塔斯马尼亚), GetPortalCommentsPageByObjectIdResponse(id=2206958, encodeId=90652206958b2, content=急求大神future oncology引文格式怎么弄啊，用endnote哪个格式和这个杂志一样啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8db8225594, createdName=ms7000000025099510, createdTime=Tue May 28 00:50:15 CST 2024, time=2024-05-28, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2206954, encodeId=6949220695495, content=求各位大神该杂志引文格式endnote里没有，选哪个比较接近？急急急，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8db8225594, createdName=ms7000000025099510, createdTime=Tue May 28 00:06:43 CST 2024, time=2024-05-28, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2126415, encodeId=ba74212641530, content=请问大家外审一般要多久啊，我1-26提交的仍然是in peer review，快三个月了都。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:12:09 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2112771, encodeId=77502112e71ff, content=这个杂志接受综述吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35248523751, createdName=ms6000000603665223, createdTime=Thu Feb 02 17:46:47 CST 2023, time=2023-02-02, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2108166, encodeId=339d2108166e5, content=兄弟们，这个期刊要不要综述啊，不是约稿的那种, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a298489693, createdName=ms2000000288456127, createdTime=Fri Dec 30 18:04:27 CST 2022, time=2022-12-30, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2108547, encodeId=6e9e210854e2c, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;放疗;基础研究 经验分享：期刊非常非常慢，去年10月投稿，今年12月接收，期间一直在under review，审稿人和编辑一起提了30多个问题，response letter字数比原文还长。。。。谨慎投兄弟们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18652547957, createdName=125366dam34暂无昵称, createdTime=Mon Jan 02 20:26:32 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126414, encodeId=a03a212641436, content=请问外审一般要多久呀？我是1-26提交的，目前仍然是in peer review。。。快三个月了5555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:09:36 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2128668, encodeId=b2e92128668cb, content=有朋友知道怎么获得future oncology 2022的全部关于肝癌的论文吗？有资源的帮帮我？电话18670664356, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af418118021, createdName=ms6000000107141238, createdTime=Thu Apr 27 14:51:33 CST 2023, time=2023-04-27, status=1, ipAttribution=上海)]

2024-05-28 ms7000000025099510 来自河北省

急求大神future oncology引文格式怎么弄啊，用endnote哪个格式和这个杂志一样啊

60 0

[GetPortalCommentsPageByObjectIdResponse(id=2190033, encodeId=46772190033b4, content=投稿3个月，状态从In Peer Review 改为Under Consideration，请问这是什么意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Thu Feb 29 09:33:12 CST 2024, time=2024-02-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2213045, encodeId=670d221304518, content=2.20投稿 5.13大修 6.7小修 7.2接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Wed Jul 03 17:39:19 CST 2024, time=2024-07-03, status=1, ipAttribution=塔斯马尼亚), GetPortalCommentsPageByObjectIdResponse(id=2206958, encodeId=90652206958b2, content=急求大神future oncology引文格式怎么弄啊，用endnote哪个格式和这个杂志一样啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8db8225594, createdName=ms7000000025099510, createdTime=Tue May 28 00:50:15 CST 2024, time=2024-05-28, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2206954, encodeId=6949220695495, content=求各位大神该杂志引文格式endnote里没有，选哪个比较接近？急急急，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8db8225594, createdName=ms7000000025099510, createdTime=Tue May 28 00:06:43 CST 2024, time=2024-05-28, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2126415, encodeId=ba74212641530, content=请问大家外审一般要多久啊，我1-26提交的仍然是in peer review，快三个月了都。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:12:09 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2112771, encodeId=77502112e71ff, content=这个杂志接受综述吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35248523751, createdName=ms6000000603665223, createdTime=Thu Feb 02 17:46:47 CST 2023, time=2023-02-02, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2108166, encodeId=339d2108166e5, content=兄弟们，这个期刊要不要综述啊，不是约稿的那种, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a298489693, createdName=ms2000000288456127, createdTime=Fri Dec 30 18:04:27 CST 2022, time=2022-12-30, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2108547, encodeId=6e9e210854e2c, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;放疗;基础研究 经验分享：期刊非常非常慢，去年10月投稿，今年12月接收，期间一直在under review，审稿人和编辑一起提了30多个问题，response letter字数比原文还长。。。。谨慎投兄弟们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18652547957, createdName=125366dam34暂无昵称, createdTime=Mon Jan 02 20:26:32 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126414, encodeId=a03a212641436, content=请问外审一般要多久呀？我是1-26提交的，目前仍然是in peer review。。。快三个月了5555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:09:36 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2128668, encodeId=b2e92128668cb, content=有朋友知道怎么获得future oncology 2022的全部关于肝癌的论文吗？有资源的帮帮我？电话18670664356, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af418118021, createdName=ms6000000107141238, createdTime=Thu Apr 27 14:51:33 CST 2023, time=2023-04-27, status=1, ipAttribution=上海)]

2024-05-28 ms7000000025099510 来自河北省

求各位大神该杂志引文格式endnote里没有，选哪个比较接近？急急急，谢谢！

0 0

[GetPortalCommentsPageByObjectIdResponse(id=2190033, encodeId=46772190033b4, content=投稿3个月，状态从In Peer Review 改为Under Consideration，请问这是什么意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Thu Feb 29 09:33:12 CST 2024, time=2024-02-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2213045, encodeId=670d221304518, content=2.20投稿 5.13大修 6.7小修 7.2接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Wed Jul 03 17:39:19 CST 2024, time=2024-07-03, status=1, ipAttribution=塔斯马尼亚), GetPortalCommentsPageByObjectIdResponse(id=2206958, encodeId=90652206958b2, content=急求大神future oncology引文格式怎么弄啊，用endnote哪个格式和这个杂志一样啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8db8225594, createdName=ms7000000025099510, createdTime=Tue May 28 00:50:15 CST 2024, time=2024-05-28, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2206954, encodeId=6949220695495, content=求各位大神该杂志引文格式endnote里没有，选哪个比较接近？急急急，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8db8225594, createdName=ms7000000025099510, createdTime=Tue May 28 00:06:43 CST 2024, time=2024-05-28, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2126415, encodeId=ba74212641530, content=请问大家外审一般要多久啊，我1-26提交的仍然是in peer review，快三个月了都。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:12:09 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2112771, encodeId=77502112e71ff, content=这个杂志接受综述吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35248523751, createdName=ms6000000603665223, createdTime=Thu Feb 02 17:46:47 CST 2023, time=2023-02-02, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2108166, encodeId=339d2108166e5, content=兄弟们，这个期刊要不要综述啊，不是约稿的那种, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a298489693, createdName=ms2000000288456127, createdTime=Fri Dec 30 18:04:27 CST 2022, time=2022-12-30, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2108547, encodeId=6e9e210854e2c, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;放疗;基础研究 经验分享：期刊非常非常慢，去年10月投稿，今年12月接收，期间一直在under review，审稿人和编辑一起提了30多个问题，response letter字数比原文还长。。。。谨慎投兄弟们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18652547957, createdName=125366dam34暂无昵称, createdTime=Mon Jan 02 20:26:32 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126414, encodeId=a03a212641436, content=请问外审一般要多久呀？我是1-26提交的，目前仍然是in peer review。。。快三个月了5555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:09:36 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2128668, encodeId=b2e92128668cb, content=有朋友知道怎么获得future oncology 2022的全部关于肝癌的论文吗？有资源的帮帮我？电话18670664356, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af418118021, createdName=ms6000000107141238, createdTime=Thu Apr 27 14:51:33 CST 2023, time=2023-04-27, status=1, ipAttribution=上海)]

2023-04-17 ms7000000764732971 来自北京

请问大家外审一般要多久啊，我1-26提交的仍然是in peer review，快三个月了都。。

90 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2190033, encodeId=46772190033b4, content=投稿3个月，状态从In Peer Review 改为Under Consideration，请问这是什么意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Thu Feb 29 09:33:12 CST 2024, time=2024-02-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2213045, encodeId=670d221304518, content=2.20投稿 5.13大修 6.7小修 7.2接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Wed Jul 03 17:39:19 CST 2024, time=2024-07-03, status=1, ipAttribution=塔斯马尼亚), GetPortalCommentsPageByObjectIdResponse(id=2206958, encodeId=90652206958b2, content=急求大神future oncology引文格式怎么弄啊，用endnote哪个格式和这个杂志一样啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8db8225594, createdName=ms7000000025099510, createdTime=Tue May 28 00:50:15 CST 2024, time=2024-05-28, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2206954, encodeId=6949220695495, content=求各位大神该杂志引文格式endnote里没有，选哪个比较接近？急急急，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8db8225594, createdName=ms7000000025099510, createdTime=Tue May 28 00:06:43 CST 2024, time=2024-05-28, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2126415, encodeId=ba74212641530, content=请问大家外审一般要多久啊，我1-26提交的仍然是in peer review，快三个月了都。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:12:09 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2112771, encodeId=77502112e71ff, content=这个杂志接受综述吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35248523751, createdName=ms6000000603665223, createdTime=Thu Feb 02 17:46:47 CST 2023, time=2023-02-02, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2108166, encodeId=339d2108166e5, content=兄弟们，这个期刊要不要综述啊，不是约稿的那种, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a298489693, createdName=ms2000000288456127, createdTime=Fri Dec 30 18:04:27 CST 2022, time=2022-12-30, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2108547, encodeId=6e9e210854e2c, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;放疗;基础研究 经验分享：期刊非常非常慢，去年10月投稿，今年12月接收，期间一直在under review，审稿人和编辑一起提了30多个问题，response letter字数比原文还长。。。。谨慎投兄弟们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18652547957, createdName=125366dam34暂无昵称, createdTime=Mon Jan 02 20:26:32 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126414, encodeId=a03a212641436, content=请问外审一般要多久呀？我是1-26提交的，目前仍然是in peer review。。。快三个月了5555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:09:36 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2128668, encodeId=b2e92128668cb, content=有朋友知道怎么获得future oncology 2022的全部关于肝癌的论文吗？有资源的帮帮我？电话18670664356, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af418118021, createdName=ms6000000107141238, createdTime=Thu Apr 27 14:51:33 CST 2023, time=2023-04-27, status=1, ipAttribution=上海)]

2023-02-02 ms6000000603665223 来自湖南省

这个杂志接受综述吗

105 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2190033, encodeId=46772190033b4, content=投稿3个月，状态从In Peer Review 改为Under Consideration，请问这是什么意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Thu Feb 29 09:33:12 CST 2024, time=2024-02-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2213045, encodeId=670d221304518, content=2.20投稿 5.13大修 6.7小修 7.2接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Wed Jul 03 17:39:19 CST 2024, time=2024-07-03, status=1, ipAttribution=塔斯马尼亚), GetPortalCommentsPageByObjectIdResponse(id=2206958, encodeId=90652206958b2, content=急求大神future oncology引文格式怎么弄啊，用endnote哪个格式和这个杂志一样啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8db8225594, createdName=ms7000000025099510, createdTime=Tue May 28 00:50:15 CST 2024, time=2024-05-28, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2206954, encodeId=6949220695495, content=求各位大神该杂志引文格式endnote里没有，选哪个比较接近？急急急，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8db8225594, createdName=ms7000000025099510, createdTime=Tue May 28 00:06:43 CST 2024, time=2024-05-28, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2126415, encodeId=ba74212641530, content=请问大家外审一般要多久啊，我1-26提交的仍然是in peer review，快三个月了都。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:12:09 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2112771, encodeId=77502112e71ff, content=这个杂志接受综述吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35248523751, createdName=ms6000000603665223, createdTime=Thu Feb 02 17:46:47 CST 2023, time=2023-02-02, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2108166, encodeId=339d2108166e5, content=兄弟们，这个期刊要不要综述啊，不是约稿的那种, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a298489693, createdName=ms2000000288456127, createdTime=Fri Dec 30 18:04:27 CST 2022, time=2022-12-30, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2108547, encodeId=6e9e210854e2c, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;放疗;基础研究 经验分享：期刊非常非常慢，去年10月投稿，今年12月接收，期间一直在under review，审稿人和编辑一起提了30多个问题，response letter字数比原文还长。。。。谨慎投兄弟们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18652547957, createdName=125366dam34暂无昵称, createdTime=Mon Jan 02 20:26:32 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126414, encodeId=a03a212641436, content=请问外审一般要多久呀？我是1-26提交的，目前仍然是in peer review。。。快三个月了5555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:09:36 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2128668, encodeId=b2e92128668cb, content=有朋友知道怎么获得future oncology 2022的全部关于肝癌的论文吗？有资源的帮帮我？电话18670664356, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af418118021, createdName=ms6000000107141238, createdTime=Thu Apr 27 14:51:33 CST 2023, time=2023-04-27, status=1, ipAttribution=上海)]

2022-12-30 ms2000000288456127 来自河南省

兄弟们，这个期刊要不要综述啊，不是约稿的那种

116 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2190033, encodeId=46772190033b4, content=投稿3个月，状态从In Peer Review 改为Under Consideration，请问这是什么意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Thu Feb 29 09:33:12 CST 2024, time=2024-02-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2213045, encodeId=670d221304518, content=2.20投稿 5.13大修 6.7小修 7.2接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Wed Jul 03 17:39:19 CST 2024, time=2024-07-03, status=1, ipAttribution=塔斯马尼亚), GetPortalCommentsPageByObjectIdResponse(id=2206958, encodeId=90652206958b2, content=急求大神future oncology引文格式怎么弄啊，用endnote哪个格式和这个杂志一样啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8db8225594, createdName=ms7000000025099510, createdTime=Tue May 28 00:50:15 CST 2024, time=2024-05-28, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2206954, encodeId=6949220695495, content=求各位大神该杂志引文格式endnote里没有，选哪个比较接近？急急急，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8db8225594, createdName=ms7000000025099510, createdTime=Tue May 28 00:06:43 CST 2024, time=2024-05-28, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2126415, encodeId=ba74212641530, content=请问大家外审一般要多久啊，我1-26提交的仍然是in peer review，快三个月了都。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:12:09 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2112771, encodeId=77502112e71ff, content=这个杂志接受综述吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35248523751, createdName=ms6000000603665223, createdTime=Thu Feb 02 17:46:47 CST 2023, time=2023-02-02, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2108166, encodeId=339d2108166e5, content=兄弟们，这个期刊要不要综述啊，不是约稿的那种, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a298489693, createdName=ms2000000288456127, createdTime=Fri Dec 30 18:04:27 CST 2022, time=2022-12-30, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2108547, encodeId=6e9e210854e2c, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;放疗;基础研究 经验分享：期刊非常非常慢，去年10月投稿，今年12月接收，期间一直在under review，审稿人和编辑一起提了30多个问题，response letter字数比原文还长。。。。谨慎投兄弟们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18652547957, createdName=125366dam34暂无昵称, createdTime=Mon Jan 02 20:26:32 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126414, encodeId=a03a212641436, content=请问外审一般要多久呀？我是1-26提交的，目前仍然是in peer review。。。快三个月了5555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:09:36 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2128668, encodeId=b2e92128668cb, content=有朋友知道怎么获得future oncology 2022的全部关于肝癌的论文吗？有资源的帮帮我？电话18670664356, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af418118021, createdName=ms6000000107141238, createdTime=Thu Apr 27 14:51:33 CST 2023, time=2023-04-27, status=1, ipAttribution=上海)]

2023-01-02 125366dam34暂无昵称

审稿速度:24.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤;放疗;基础研究
经验分享：期刊非常非常慢，去年10月投稿，今年12月接收，期间一直在under review，审稿人和编辑一起提了30多个问题，response letter字数比原文还长。。。。谨慎投兄弟们

111 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2190033, encodeId=46772190033b4, content=投稿3个月，状态从In Peer Review 改为Under Consideration，请问这是什么意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Thu Feb 29 09:33:12 CST 2024, time=2024-02-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2213045, encodeId=670d221304518, content=2.20投稿 5.13大修 6.7小修 7.2接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Wed Jul 03 17:39:19 CST 2024, time=2024-07-03, status=1, ipAttribution=塔斯马尼亚), GetPortalCommentsPageByObjectIdResponse(id=2206958, encodeId=90652206958b2, content=急求大神future oncology引文格式怎么弄啊，用endnote哪个格式和这个杂志一样啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8db8225594, createdName=ms7000000025099510, createdTime=Tue May 28 00:50:15 CST 2024, time=2024-05-28, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2206954, encodeId=6949220695495, content=求各位大神该杂志引文格式endnote里没有，选哪个比较接近？急急急，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8db8225594, createdName=ms7000000025099510, createdTime=Tue May 28 00:06:43 CST 2024, time=2024-05-28, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2126415, encodeId=ba74212641530, content=请问大家外审一般要多久啊，我1-26提交的仍然是in peer review，快三个月了都。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:12:09 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2112771, encodeId=77502112e71ff, content=这个杂志接受综述吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35248523751, createdName=ms6000000603665223, createdTime=Thu Feb 02 17:46:47 CST 2023, time=2023-02-02, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2108166, encodeId=339d2108166e5, content=兄弟们，这个期刊要不要综述啊，不是约稿的那种, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a298489693, createdName=ms2000000288456127, createdTime=Fri Dec 30 18:04:27 CST 2022, time=2022-12-30, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2108547, encodeId=6e9e210854e2c, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;放疗;基础研究 经验分享：期刊非常非常慢，去年10月投稿，今年12月接收，期间一直在under review，审稿人和编辑一起提了30多个问题，response letter字数比原文还长。。。。谨慎投兄弟们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18652547957, createdName=125366dam34暂无昵称, createdTime=Mon Jan 02 20:26:32 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126414, encodeId=a03a212641436, content=请问外审一般要多久呀？我是1-26提交的，目前仍然是in peer review。。。快三个月了5555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:09:36 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2128668, encodeId=b2e92128668cb, content=有朋友知道怎么获得future oncology 2022的全部关于肝癌的论文吗？有资源的帮帮我？电话18670664356, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af418118021, createdName=ms6000000107141238, createdTime=Thu Apr 27 14:51:33 CST 2023, time=2023-04-27, status=1, ipAttribution=上海)]

2023-04-17 ms7000000764732971 来自北京

请问外审一般要多久呀？我是1-26提交的，目前仍然是in peer review。。。快三个月了5555

90 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2190033, encodeId=46772190033b4, content=投稿3个月，状态从In Peer Review 改为Under Consideration，请问这是什么意思？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Thu Feb 29 09:33:12 CST 2024, time=2024-02-29, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2213045, encodeId=670d221304518, content=2.20投稿 5.13大修 6.7小修 7.2接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Wed Jul 03 17:39:19 CST 2024, time=2024-07-03, status=1, ipAttribution=塔斯马尼亚), GetPortalCommentsPageByObjectIdResponse(id=2206958, encodeId=90652206958b2, content=急求大神future oncology引文格式怎么弄啊，用endnote哪个格式和这个杂志一样啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8db8225594, createdName=ms7000000025099510, createdTime=Tue May 28 00:50:15 CST 2024, time=2024-05-28, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2206954, encodeId=6949220695495, content=求各位大神该杂志引文格式endnote里没有，选哪个比较接近？急急急，谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8db8225594, createdName=ms7000000025099510, createdTime=Tue May 28 00:06:43 CST 2024, time=2024-05-28, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2126415, encodeId=ba74212641530, content=请问大家外审一般要多久啊，我1-26提交的仍然是in peer review，快三个月了都。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:12:09 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2112771, encodeId=77502112e71ff, content=这个杂志接受综述吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35248523751, createdName=ms6000000603665223, createdTime=Thu Feb 02 17:46:47 CST 2023, time=2023-02-02, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2108166, encodeId=339d2108166e5, content=兄弟们，这个期刊要不要综述啊，不是约稿的那种, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a298489693, createdName=ms2000000288456127, createdTime=Fri Dec 30 18:04:27 CST 2022, time=2022-12-30, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2108547, encodeId=6e9e210854e2c, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤;放疗;基础研究 经验分享：期刊非常非常慢，去年10月投稿，今年12月接收，期间一直在under review，审稿人和编辑一起提了30多个问题，response letter字数比原文还长。。。。谨慎投兄弟们, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=18652547957, createdName=125366dam34暂无昵称, createdTime=Mon Jan 02 20:26:32 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126414, encodeId=a03a212641436, content=请问外审一般要多久呀？我是1-26提交的，目前仍然是in peer review。。。快三个月了5555, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b09c5466252, createdName=ms7000000764732971, createdTime=Mon Apr 17 04:09:36 CST 2023, time=2023-04-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2128668, encodeId=b2e92128668cb, content=有朋友知道怎么获得future oncology 2022的全部关于肝癌的论文吗？有资源的帮帮我？电话18670664356, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af418118021, createdName=ms6000000107141238, createdTime=Thu Apr 27 14:51:33 CST 2023, time=2023-04-27, status=1, ipAttribution=上海)]

2023-04-27 ms6000000107141238 来自上海

有朋友知道怎么获得future oncology 2022的全部关于肝癌的论文吗？有资源的帮帮我？电话18670664356

89 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务